ENvue Medical Adds to Intellectual Property Portfolio by Securing USPTO Notice of Allowance for Ultrasound-Enhanced Cannabinoid Drug Delivery Technology

ENvue Medical (NASDAQ: FEED) received a USPTO Notice of Allowance for U.S. Patent Application No. 17/025,969 on May 8, 2026, covering a surface acoustic wave (SAW) ultrasound-enhanced system for transdermal delivery of cannabinoid therapeutics.

Rhea-AI Summary

ENvue Medical (NASDAQ: FEED) received a USPTO Notice of Allowance for U.S. Patent Application No. 17/025,969 on May 8, 2026, covering a surface acoustic wave (SAW) ultrasound-enhanced system for transdermal delivery of cannabinoid therapeutics.

The allowed claims span transdermal patch configurations, portable SAW-generating platforms, and methods that the company says produce synergistic enhancement of cannabinoid skin absorption versus patch-only administration. The company says the allowance broadens its IP footprint and could enable future collaborations and applications beyond existing marketed products.

Positive

• USPTO Notice of Allowance for SAW-enhanced cannabinoid transdermal delivery
• Broad claim scope covering patches, portable SAW platforms, and delivery methods
• Extends SAW platform into therapeutic drug-delivery applications beyond feeding tubes

Negative

• No commercialization timeline or revenue guidance disclosed for the patented technology

Argus May 8 session

-9.85% close to close Open Argus

Details

News Market Reaction – FEED

In the May 8 session, FEED declined 9.85%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock moved -9.8% in the session following this news. A negative reaction despite this patent al...

Analysis

The stock moved -9.8% in the session following this news. A negative reaction despite this patent allowance would contrast with prior positive responses to IP wins, such as the 5.6% moves following earlier Notices of Allowance and the 58.04% gain on footprint expansion. The news adds a new therapeutic dimension to the SAW platform but comes while the stock trades well below its 200-day MA and 52-week high. Past instances of divergence on otherwise constructive updates highlight that investors have sometimes discounted progress amid broader concerns.

Key Figures

Hospitals under GPO system: Over 90 hospitals States covered: 17 states Contract term: Through 2028 +5 more

Hospitals under GPO system

Over 90 hospitals

Health system covered by three-year purchasing agreement renewal

States covered

17 states

Geographic reach of GPO health system renewal through 2028

Contract term

Through 2028

Three-year purchasing agreement renewal for ENvue products

U.S. hospital customer count

40th U.S. hospital

Virginia medical center adopting ENvue Navigation Platform

Medical center size

255-bed

Virginia nonprofit medical center adopting ENvue platform

Hospital footprint

39 U.S. hospitals

ENvue Navigation Platform deployment as of corporate update

Patent claims

18 claims

USPTO Notice of Allowance for feeding tube with sensor and camera

Major holder shares

240,000 shares (6.5%)

Schedule 13D/A reporting unchanged beneficial ownership

Historical Context

5 past events · Latest: May 07

5 events

1. May 07

   Purchasing agreement renewal

   24h Move

   +5.6%

   Three-year GPO purchasing agreement renewal covering a large U.S. health system.

2. Apr 20

   New hospital customer

   24h Move

   -4.4%

   40th U.S. hospital adoption of ENvue Navigation Platform at a 255-bed medical center.

3. Apr 16

   Stockholder letter update

   24h Move

   -7.5%

   Corporate update on 39 U.S. hospitals, recurring revenue, and new patent allowance.

4. Mar 24

   Hospital footprint expansion

   24h Move

   +58.0%

   Purchase expanding footprint to 39 hospitals including a 714-bed trauma center in Michigan.

5. Feb 24

   Patent portfolio expansion

   24h Move

   +5.6%

   USPTO Notice of Allowance for feeding tube with electromagnetic sensor and camera.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

notice of allowance, surface acoustic wave, transdermal, cannabinoid-based therapeutics, +3 more

7 terms

notice of allowance regulatory

"announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance"

A notice of allowance is an official confirmation from a patent office that a patent application has met all necessary requirements and is approved for granting. It signals that the invention is likely to receive legal protection soon, which can be important for investors considering the value and exclusivity of a new product or technology. Think of it as a green light indicating that the invention is on track to become legally protected.

surface acoustic wave medical

"covering a novel drug delivery system utilizing the Company's proprietary surface acoustic wave (SAW) technology"

A surface acoustic wave is a tiny mechanical vibration that travels along the surface of a solid, like a ripple moving across a pond but at ultrasonic frequencies and microscopic scale. Used in electronic components such as filters, sensors and timing devices, these waves determine how well products handle signals and sensing tasks, so improvements, shortages or cost changes in SAW technology can directly affect a maker’s performance, margins and competitive position.

transdermal medical

"SAW technology to enhance transdermal delivery of cannabinoid-based therapeutics"

Transdermal describes a method of delivering a drug through the skin so the active ingredient is absorbed into the bloodstream, commonly via a patch, gel or cream. For investors, transdermal delivery affects a product’s convenience, steady dosing, patent and regulatory profile, manufacturing needs and market appeal—similar to a slow-release battery that makes a device easier to use and last longer, which can influence sales potential and risk.

cannabinoid-based therapeutics medical

"Cannabinoid-based therapeutics continue to attract growing scientific, pharmaceutical, and commercial interest"

Medicines and medical products that are derived from or mimic compounds found in the cannabis plant, developed to treat symptoms or diseases through controlled dosing and delivery. Investors care because these therapeutics sit at the intersection of health care and a shifting regulatory and consumer landscape, so clinical results, approval decisions, and manufacturing scalability can quickly affect a company’s sales and growth potential—think of them as new recipes where successful trials and legal approval unlock market access.

uspto regulatory

"the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance"

United States Patent and Trademark Office (USPTO) is the federal agency that reviews and issues patents for inventions and registers trademarks for brand names and logos. For investors, USPTO decisions act like a gatekeeper for a company’s legal right to exclude competitors — similar to a property deed for ideas and brands — which can protect revenue, support pricing power, and affect a company’s long‑term value and risk profile.

510(k) cleared regulatory

"The platform is FDA 510(k) cleared for adult use and provides real-time bedside visualization"

A 510(k) clearance is the U.S. Food and Drug Administration’s permission to market a medical device after the manufacturer shows it is sufficiently similar to one already legally sold. Think of it as getting a green light for a new product because it behaves like an approved model; it allows sales in the U.S. faster than a full approval and reduces regulatory risk, which can materially affect a company’s revenue prospects and valuation.

schedule 13d/a regulatory

""[SCHEDULE 13D/A] ENvue Medical, Inc. Amended Major Shareholder Report""

A Schedule 13D/A is an amended disclosure filed with regulators by an investor who already reported owning more than 5% of a company’s shares and needs to update their original filing. Think of it as a public status update that tells markets whether the investor’s ownership, plans, or source of funds have changed; such updates matter because they can signal a push for control, major strategic moves, or increased pressure on management, which can affect stock prices.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Patent Expands Company's Proprietary Surface Acoustic Wave Platform into Advanced Therapeutic Delivery Applications

TYLER, Texas, May 08, 2026 (GLOBE NEWSWIRE) -- ENvue Medical, Inc. (NASDAQ: FEED) ("ENvue," "ENvue Medical" or the "Company"), a commercial-stage medical device company focused on real-time guided bedside feeding tube placement, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/025,969, covering a novel drug delivery system utilizing the Company's proprietary surface acoustic wave (SAW) technology to enhance transdermal delivery of cannabinoid-based therapeutics.

The allowed claims provide broad intellectual property protection across multiple components of the combined SAW ultrasound and cannabinoid transdermal delivery system, including transdermal patch configurations, portable SAW-generating platforms, and methods shown to produce synergistic enhancement in cannabinoid absorption through the skin compared to administration via the transdermal patch alone.

Cannabinoid-based therapeutics continue to attract growing scientific, pharmaceutical, and commercial interest globally, particularly in pain management, neurology, inflammation, and chronic disease applications. ENvue Medical believes its ultrasound-based delivery platform may provide future opportunities to improve therapeutic administration and enable strategic collaborations across multiple treatment categories.

"This Notice of Allowance validates a meaningful expansion of our SAW platform into an entirely new therapeutic category,” said Doron Besser, MD, Chief Executive Officer of ENvue Medical. “We believe that the USPTO's recognition of the synergistic effect between our ultrasound technology and cannabinoid transdermal delivery, and its determination that this combination was non-obvious, reflects the depth and breadth of our intellectual property portfolio. We believe this positions ENvue favorably as interest in cannabinoid-based therapeutics continues to grow, and we look forward to exploring the strategic opportunities this patent creates for the Company."

The Company believes this patent allowance further reinforces the value and versatility of its proprietary SAW technology platform and highlights the potential for future applications beyond its currently marketed products.

About ENvue Medical, Inc.
ENvue Medical, Inc. (NASDAQ: FEED) is a medical technology company specializing in the advancement of intelligent, non-invasive solutions for enteral care across clinical and home care settings. Headquartered in Tyler, Texas, with research and development in Tel-Aviv and Nesher, Israel, the Company focuses on two distinct technology platforms:

• ENvue™ Navigation Platform, developed and operated by ENvue Medical Inc., with offices in Arlington Heights, Illinois, and Tel-Aviv, Israel, is a minimally invasive electromagnetic navigation system intended to assist clinicians in placing feeding tubes into the gastrointestinal tract. FDA 510(k) cleared for adult use, ENvue provides real-time bedside visualization of tube movement and supports informed decision-making during the placement procedure. Future platform expansion may include pediatric and vascular access applications.
• ENvue Medical aims to advance standards in non-invasive therapy and minimally invasive navigation, with a commitment to patient safety, clinical usability, and technology innovation across a range of healthcare environments.
• Acoustic-based therapeutic technologies, including PainShield® and UroShield®, which utilize proprietary low-intensity surface acoustic wave (SAW) technology. These devices are intended for use in home or care settings and are designed to treat pain, reduce bacterial colonization, and disrupt biofilms.
  

Forward-Looking Statements
This press release contains “forward-looking statements.” Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential,” or similar words. These forward-looking statements include, but are not limited to: statements regarding the adoption and implementation of ENvue Medical’s platforms, anticipated commercial expansion, growth, scalability, and implementation of ENvue Medical’s products, the success of ENvue’s programs, market interest in the Company’s technology, and future expectations for strategic growth. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company’s control and cannot be predicted or quantified; consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: (i) market acceptance of the Company’s existing and new products; (ii) clinical performance and operational outcomes; (iii) delays or complications in product implementation; (iv) intense competition in the medical device industry; (v) product liability or performance issues; (vi) limitations in manufacturing or supply chain capabilities; (vii) reimbursement limitations; (viii) intellectual property protection; (ix) healthcare regulatory changes in the U.S. and abroad; and (x) the need for additional capital. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Investors and security holders are urged to read these documents free of charge at: www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events, or otherwise, except as required by law.

Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
PH: (212) 896-1254
envue@kcsa.com

Media Contact:
KCSA Strategic Communications
Michaela Fawcett, Senior Account Director
PH: (978) 995-4683
envue@kcsa.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did ENvue Medical (FEED) announce on May 8, 2026 about its patent?

ENvue announced a USPTO Notice of Allowance for a SAW-enhanced cannabinoid transdermal delivery patent. According to the company, the allowed claims cover patches, portable SAW platforms, and methods that enhance cannabinoid absorption through skin versus patch alone.

What does the allowed patent for ENvue (FEED) cover specifically?

The allowed patent covers transdermal patch configurations, portable SAW platforms, and delivery methods. According to the company, those claims provide broad IP protection across components of the combined SAW ultrasound and cannabinoid transdermal system.

How might the FEED patent affect ENvue's SAW technology strategy?

The patent broadens the SAW platform into therapeutic drug delivery beyond feeding tubes. According to the company, this may enable future strategic collaborations across pain, neurology, inflammation, and chronic disease applications.

Does ENvue (FEED) disclose commercial plans or revenue from the new patent?

No commercial timeline or revenue guidance was provided in the announcement. According to the company, the allowance highlights potential opportunities but did not specify commercialization timelines or expected financial impact.

What is the significance of a USPTO Notice of Allowance for FEED shareholders?

A Notice of Allowance indicates the USPTO will grant claims after formalities are completed. According to the company, the allowance reinforces the SAW platform's IP value and potential to support future partnerships and applications.